blog counter

Clearant, Inc.
HCID Member | Biotech Specialty Pharma
11111 Santa Monica Boulevard, Suite 650
Los Angeles, CA 90025 USA
phone: 310-479-4570
fax:
Symbol CLRA
Exchange .OB
Founded 0
Employees 7
www.clearant.com
Research Sector Biotech Specialty Pharma
Summary Description
Pathogen inactivating technology for the reduced contamination of biological products
Management
Jon M. Garfield, Chief Executive Officer; John Wehrle, Chairman; Dr. Hervé de Kergrohen, Director; Dr. Nolan Sigal, Director; Alexander Man-Kit Ngan, Director
Ownership
Financials Mkt Cap :6


* numbers in thousands

Recent Results
For the first quarter ended March 2006, revenues increased 78% to $190,000. The net loss for the quarter was $2,513 compared to a loss of $3,100 for the first quarter of 2005.
 
Keywords
pathogen inactivation technology, tissue allograft implants, Plasma therapies, Blood products, Recombinant products, j2008a

Comment | Printable Version | Jun. 12, 2008
If you work for Clearant, Inc. and want to update this profile, click here

Description
Clearant Corporation, a biotechnology company, develops and markets pathogen inactivation technology. The Clearant Process reduces the risk of contamination of biological products.
Products / Services
The Clearant Process: Pathogen inactivation is used on biological products including: tissue allograft implants, plasma therapies, blood products, recombinant products.
Technology / Differentiation
The Clearant Process is based on exposing a biological product to gamma-irradiation that delivers a predetermined amount of radiation to inactivate a desired level of pathogens. This process reduces the risk of contamination while preserving the functionality and integrity of the treated product. The Process is used in both intermediate and final stages of production and can be applied to products after they have been sealed into their final packages.
Market / Customers
Two million Americans undergo orthopedic and spinal surgeries that could be made safer with the company's technology. The Process is intended to address safety concerns for allografts and certain other biological products. The Clearant process is marketed to tissue banks, pharmaceutical and biotechnology companies.
Strategy
Clearant will continue to add license agreement in its existing markets. Additionally, Clearant intends to generate recurring revenues from irradiation services. In September 2005, Clearant launched a new sterilization service which allows tissue banks to send ready for sterilization tissue to their facility to irradiated by Clearant. launched a new sterilization service which allows tissue banks to send ready for sterilization tissue to their facility to irradiated by Clearant.
Status
Clearant has signed 11 license agreements with customers to utilize the Clearant Process with its products. Ten of the agreements are with tissue banks - 6 license agreements and 4 sterilization service agreements. It also has a license agreement with a recombiniant manufacturer.